CA2166890A1 - Amelioration de l'inhibition par les oligonucleotides de la production de proteines, de la proliferation cellulaire et (ou) de la multiplication d'agents pathogenes de maladies infectieuses - Google Patents

Amelioration de l'inhibition par les oligonucleotides de la production de proteines, de la proliferation cellulaire et (ou) de la multiplication d'agents pathogenes de maladies infectieuses

Info

Publication number
CA2166890A1
CA2166890A1 CA002166890A CA2166890A CA2166890A1 CA 2166890 A1 CA2166890 A1 CA 2166890A1 CA 002166890 A CA002166890 A CA 002166890A CA 2166890 A CA2166890 A CA 2166890A CA 2166890 A1 CA2166890 A1 CA 2166890A1
Authority
CA
Canada
Prior art keywords
oligonucleotide
targeted
nucleic acid
subtargeted
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002166890A
Other languages
English (en)
Inventor
Nanibhushan Dattagupta
C. Nagaraja Sridhar
Daniel L. Kacian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gen Probe Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2166890A1 publication Critical patent/CA2166890A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un premier oligonucleotide ciblé purifié conjointement avec 1) un oligonucléotide sous-ciblé, 2) un deuxième oligonucléotide ciblé, ou 3) un oligonucléotide de phosphorothioate non ciblé de manière à inhiber la production protéique d'une séquence d'acides nucléiques ciblée, la prolifération cellulaire et/ou la multiplication d'un organisme étranger. L'oligonucléotide sous-ciblé contient une version tronquée de l'oligonucléotide ciblé.
CA002166890A 1993-07-19 1994-07-19 Amelioration de l'inhibition par les oligonucleotides de la production de proteines, de la proliferation cellulaire et (ou) de la multiplication d'agents pathogenes de maladies infectieuses Abandoned CA2166890A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9380093A 1993-07-19 1993-07-19
US08/093,800 1993-07-19

Publications (1)

Publication Number Publication Date
CA2166890A1 true CA2166890A1 (fr) 1995-02-02

Family

ID=22240803

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002166890A Abandoned CA2166890A1 (fr) 1993-07-19 1994-07-19 Amelioration de l'inhibition par les oligonucleotides de la production de proteines, de la proliferation cellulaire et (ou) de la multiplication d'agents pathogenes de maladies infectieuses

Country Status (6)

Country Link
EP (1) EP0781332A2 (fr)
JP (1) JPH09500787A (fr)
KR (1) KR960704034A (fr)
AU (1) AU689129B2 (fr)
CA (1) CA2166890A1 (fr)
WO (1) WO1995003406A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714436B1 (fr) * 1993-07-19 2003-05-07 Gen-Probe Incorporated Oligonucleotides actifs contre le virus de l'immunodeficience humaine
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US5747470A (en) * 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
AU705122B2 (en) * 1995-06-07 1999-05-13 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
US5674995A (en) * 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CZ295108B6 (cs) 1998-03-20 2005-05-18 Benitec Australia Ltd Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP2314700A1 (fr) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition et méthode destinées à l'attenuation in vivo et in vitro de l'expression génique utilisant de l'ARN double brin
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
DE102004038535B4 (de) * 2004-08-06 2012-10-04 Universitätsklinikum Schleswig-Holstein Zelluläre Einschleusung von Nukleinsäurewirkstoffen
ES2647452T3 (es) 2006-08-08 2017-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Estructura y uso de oligonucleótidos 5' fosfato
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (fr) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification d'oligonucléotides triphosphorylés au moyen d'étiquettes de capture
EP2712870A1 (fr) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Nouveaux ligands de RIG-I et procédés pour les produire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5030557A (en) * 1987-11-24 1991-07-09 Ml Technology Venture Means and method for enhancing nucleic acid hybridization
CA2104698A1 (fr) * 1991-02-21 1992-08-22 John J. Toole Aptameres specifiques de biomolecules et methodes de production
DK0625194T3 (da) * 1992-02-04 1996-05-28 Worcester Found Ex Biology Forøgelse af ribozym-katalytisk aktivitet med et tilstødende facilitator oligonukleotid

Also Published As

Publication number Publication date
WO1995003406A2 (fr) 1995-02-02
JPH09500787A (ja) 1997-01-28
AU7550594A (en) 1995-02-20
KR960704034A (ko) 1996-08-31
WO1995003406A3 (fr) 1995-09-14
AU689129B2 (en) 1998-03-26
EP0781332A2 (fr) 1997-07-02

Similar Documents

Publication Publication Date Title
US5874281A (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
CA2166889C (fr) Oligonucleotides actifs contre le virus de l'immunodeficience humaine
EP0677056B1 (fr) Alkylphosphonates et alkylphosphonothioates d'oligonucleotides
AU689129B2 (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
EP0748382B1 (fr) Acide nucleique enzymatique contenant un non-nucleotide
US5693773A (en) Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US6372427B1 (en) Cooperative oligonucleotides
WO1995003406A9 (fr) Augmentation de l'inhibition oligonucleotidique de la production proteique, de la proliferation cellulaire et/ou de la multiplication d'agents pathogenes de maladie infectieuse
Ma et al. Synthetic oligonucleotides as therapeutics: the coming of age
US6489464B1 (en) Branched oligonucleotides as pathogen-inhibitory agents
Cohen Oligonucleotides as therapeutic agents
CA2436519A1 (fr) Selection d'acides nucleiques catalytiques cibles sur des agents infectieux
AU699233B2 (en) Compounds and methods for inhibiting propagation of human immunodeficiency virus
Pollock et al. Antisense oligonucleotides: a survey of recent literature, possible mechanisms of action and therapeutic progress
WO1997038097A1 (fr) Oligonucleotides cooperatifs
US6828148B2 (en) Miniribozymes active at low magnesium ion concentrations
Galderisi et al. Antisense oligonucleotides as drugs for HIV treatment
AU1457195A (en) Non-nucleotide containing enzymatic nucleic acid

Legal Events

Date Code Title Description
FZDE Dead